Avextra plans a Phase 2 trial in Italy to test a cannabis-based oral medicine to ease symptoms in ALS and other ...

Researchers have developed a type of gene therapy that selectively targets diseased nerve cells in ALS while leaving healthy ...

Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its ...

Differences in human tears in ALS can distinguish bulbar-onset disease from spinal-onset ALS, making this a possible ...

In an ALS study, growth factor FGF4 reduced the activity of star-shaped cells called astrocytes but did not stop motor ...

Modality.AI and Target ALS are partnering on a clinical study of AI as a way to assess changes in speech and motor function ...

Changes in the production of several immune proteins at the time of an ALS diagnosis were linked to disease progression in ...

The past is always present, we're told, and that's a comfort for columnist Kristin Neva when she can focus on good memories from before ALS.

The new patent covers Neurosense's formulation of PrimeC, a fixed-dose combo of an approved antibiotic and anti-inflammatory.

ProJenX teamed with Unlearn to create digital twins of ALS patients as a placebo group in open-label extension of Phase 1 ...

The Mayo Clinic was awarded $12 million to support a study that will give ALS patients access to the investigational therapy ...